These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37634215)

  • 61. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
    Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
    Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epigenetic Therapy for Epithelioid Sarcoma.
    Rothbart SB; Baylin SB
    Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
    Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
    Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
    Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
    Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 66. lncRNA PVT1 promotes hepatitis B virus‑positive liver cancer progression by disturbing histone methylation on the c‑Myc promoter.
    Jiang B; Yang B; Wang Q; Zheng X; Guo Y; Lu W
    Oncol Rep; 2020 Feb; 43(2):718-726. PubMed ID: 31894346
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
    Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
    Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
    [TBL] [Abstract][Full Text] [Related]  

  • 68. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
    Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
    Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
    Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
    Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
    Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
    Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Refining the management of relapsed or refractory follicular lymphoma.
    Pagel JM; Burke JM; Leslie LA
    Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting epigenetics in sarcomas through EZH2 inhibition.
    Italiano A
    J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition.
    Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
    Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
    [TBL] [Abstract][Full Text] [Related]  

  • 76. LncRNA MALAT1 promotes epithelial-to-mesenchymal transition of esophageal cancer through Ezh2-Notch1 signaling pathway.
    Chen M; Xia Z; Chen C; Hu W; Yuan Y
    Anticancer Drugs; 2018 Sep; 29(8):767-773. PubMed ID: 29916899
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A patent review of EZH2 inhibitors from 2017 and beyond.
    Wan G; Feng H; Su C; Zhu Y; Zhang L; Zhang Q; Yu L
    Expert Opin Ther Pat; 2023 Apr; 33(4):293-308. PubMed ID: 37095742
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of histone methyltransferase inhibitors in cancer treatment: A systematic review.
    Marzochi LL; Cuzziol CI; Nascimento Filho CHVD; Dos Santos JA; Castanhole-Nunes MMU; Pavarino ÉC; Guerra ENS; Goloni-Bertollo EM
    Eur J Pharmacol; 2023 Apr; 944():175590. PubMed ID: 36775112
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
    Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
    J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt's lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib.
    Jeong Y; Kim SB; Yang CE; Yu MS; Choi WS; Jeon Y; Lim JY
    Front Oncol; 2023; 13():1252658. PubMed ID: 37752998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.